JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

NCT07336823 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: JY232 Injection

Sponsor

Shenzhen Genocury Biotech Co., Ltd.